JP2010538049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010538049A5 JP2010538049A5 JP2010523523A JP2010523523A JP2010538049A5 JP 2010538049 A5 JP2010538049 A5 JP 2010538049A5 JP 2010523523 A JP2010523523 A JP 2010523523A JP 2010523523 A JP2010523523 A JP 2010523523A JP 2010538049 A5 JP2010538049 A5 JP 2010538049A5
- Authority
- JP
- Japan
- Prior art keywords
- xaa
- ethoxy
- glp
- carboxy
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 68
- -1 (1-amino) Cyclohexyl Chemical group 0.000 claims description 27
- 150000001408 amides Chemical group 0.000 claims description 24
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- CNMAQBJBWQQZFZ-LURJTMIESA-N (2s)-2-(pyridin-2-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CC=N1 CNMAQBJBWQQZFZ-LURJTMIESA-N 0.000 claims description 7
- WTKYBFQVZPCGAO-LURJTMIESA-N (2s)-2-(pyridin-3-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=CN=C1 WTKYBFQVZPCGAO-LURJTMIESA-N 0.000 claims description 7
- SAAQPSNNIOGFSQ-LURJTMIESA-N (2s)-2-(pyridin-4-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NC1=CC=NC=C1 SAAQPSNNIOGFSQ-LURJTMIESA-N 0.000 claims description 7
- KQMBIBBJWXGSEI-ROLXFIACSA-N (2s)-2-amino-3-hydroxy-3-(1h-imidazol-5-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)C(O)C1=CNC=N1 KQMBIBBJWXGSEI-ROLXFIACSA-N 0.000 claims description 7
- AJFGLTPLWPTALJ-SSDOTTSWSA-N (2s)-2-azaniumyl-2-(fluoromethyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound FC[C@@](N)(C(O)=O)CC1=CN=CN1 AJFGLTPLWPTALJ-SSDOTTSWSA-N 0.000 claims description 7
- MSECZMWQBBVGEN-LURJTMIESA-N (2s)-2-azaniumyl-4-(1h-imidazol-5-yl)butanoate Chemical compound OC(=O)[C@@H](N)CCC1=CN=CN1 MSECZMWQBBVGEN-LURJTMIESA-N 0.000 claims description 7
- UYEGXSNFZXWSDV-BYPYZUCNSA-N (2s)-3-(2-amino-1h-imidazol-5-yl)-2-azaniumylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CNC(N)=N1 UYEGXSNFZXWSDV-BYPYZUCNSA-N 0.000 claims description 7
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 claims description 7
- IINRZEIPFQHEAP-UHFFFAOYSA-N 1-aminocycloheptane-1-carboxylic acid Chemical compound OC(=O)C1(N)CCCCCC1 IINRZEIPFQHEAP-UHFFFAOYSA-N 0.000 claims description 7
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 claims description 7
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 claims description 7
- PJSQECUPWDUIBT-UHFFFAOYSA-N 1-azaniumylcyclooctane-1-carboxylate Chemical compound OC(=O)C1(N)CCCCCCC1 PJSQECUPWDUIBT-UHFFFAOYSA-N 0.000 claims description 7
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims description 7
- 229930195721 D-histidine Natural products 0.000 claims description 7
- HRRYYCWYCMJNGA-ZETCQYMHSA-N alpha-methyl-L-histidine Chemical compound OC(=O)[C@](N)(C)CC1=CN=CN1 HRRYYCWYCMJNGA-ZETCQYMHSA-N 0.000 claims description 7
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 7
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims description 7
- 229960002885 histidine Drugs 0.000 claims description 7
- OQQDUMSNEFAJOO-MRVPVSSYSA-N (2r)-2-amino-2-(1h-imidazol-5-ylmethyl)-3-oxobutanoic acid Chemical compound CC(=O)[C@@](N)(C(O)=O)CC1=CN=CN1 OQQDUMSNEFAJOO-MRVPVSSYSA-N 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 claims 20
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 20
- 150000001413 amino acids Chemical group 0.000 claims 13
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 12
- 229940024606 amino acid Drugs 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 208000029078 coronary artery disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 2
- 201000001421 hyperglycemia Diseases 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 claims 1
- 230000001079 digestive effect Effects 0.000 claims 1
- 201000006549 dyspepsia Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 0 C*NCCC(C)(C)OCCOCCC1OC1 Chemical compound C*NCCC(C)(C)OCCOCCC1OC1 0.000 description 3
- FZKHGEQUJKGXCB-UHFFFAOYSA-N CC(CCNC)/[O]=C/COCCNC(COCC(N)=O)=O Chemical compound CC(CCNC)/[O]=C/COCCNC(COCC(N)=O)=O FZKHGEQUJKGXCB-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07115743 | 2007-09-05 | ||
| EP08101010 | 2008-01-28 | ||
| PCT/EP2008/061833 WO2009030774A1 (en) | 2007-09-05 | 2008-09-05 | Truncated glp-1 derivatives and their therapeutical use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010538049A JP2010538049A (ja) | 2010-12-09 |
| JP2010538049A5 true JP2010538049A5 (enExample) | 2013-11-21 |
Family
ID=40043001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010523523A Withdrawn JP2010538049A (ja) | 2007-09-05 | 2008-09-05 | 切断型ｇｌｐ−１誘導体及びその治療的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100292133A1 (enExample) |
| EP (1) | EP2190873B1 (enExample) |
| JP (1) | JP2010538049A (enExample) |
| CN (1) | CN101842386A (enExample) |
| ES (1) | ES2550363T3 (enExample) |
| WO (1) | WO2009030774A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
| CN101578102B (zh) | 2007-01-05 | 2013-07-17 | 印第安纳大学研究及科技有限公司 | 在生理性pH缓冲液中显示增强的溶解性的胰高血糖素类似物 |
| MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
| JP5771005B2 (ja) | 2007-10-30 | 2015-08-26 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | グルカゴンアンタゴニスト及びｇｌｐ−１アゴニスト活性を示す化合物 |
| CA2707861A1 (en) | 2007-10-30 | 2009-05-07 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| EP2300037B1 (en) | 2008-06-17 | 2016-03-30 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| TWI541023B (zh) | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ｐｈ緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
| TWI474835B (zh) | 2008-06-17 | 2015-03-01 | Univ Indiana Res & Tech Corp | 用於治療代謝病症及肥胖症之基於ｇｉｐ之混合激動劑 |
| RU2550696C2 (ru) | 2008-12-19 | 2015-05-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Основанные на амидах пролекарства пептидов глюкагонового надсемейства |
| WO2010148089A1 (en) | 2009-06-16 | 2010-12-23 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| US8703701B2 (en) | 2009-12-18 | 2014-04-22 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP2528618A4 (en) | 2010-01-27 | 2015-05-27 | Univ Indiana Res & Tech Corp | GLUCAGON ANTAGONISTE AND GIP AGONISTS CONJUGATES AND COMPOSITIONS FOR THE TREATMENT OF METABOLISM DISEASES AND ADIPOSITAS |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| CA2797095A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting nuclear hormone receptor activity |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| MX2012014576A (es) | 2010-06-24 | 2013-02-21 | Univ Indiana Res & Tech Corp | Profarmacos de peptido de la superfamilia de glucagon basado en amida. |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| PL2651398T3 (pl) | 2010-12-16 | 2018-05-30 | Novo Nordisk A/S | Stałe kompozycje zawierające agonistę GLP-1 i sól kwasu N-(8-(2-hydroksybenzoilo)amino)kaprylowego |
| WO2012088116A2 (en) | 2010-12-22 | 2012-06-28 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting gip receptor activity |
| DK2696687T3 (en) | 2011-04-12 | 2017-02-06 | Novo Nordisk As | Double-acylated GLP-1 derivatives |
| CN103857408B (zh) | 2011-06-22 | 2017-04-12 | 印第安那大学科技研究公司 | 胰高血糖素/glp‑1受体协同激动剂 |
| MX2013015168A (es) | 2011-06-22 | 2014-03-31 | Univ Indiana Res & Tech Corp | Co-agonista del receptor de glucagon/glp-1. |
| CN107266558A (zh) | 2011-09-06 | 2017-10-20 | 诺沃—诺迪斯克有限公司 | Glp‑1衍生物 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HK1198810A1 (en) | 2011-11-17 | 2015-06-12 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting glucocorticoid receptor activity |
| HUE042757T2 (hu) | 2012-03-22 | 2019-07-29 | Novo Nordisk As | Szállító szert tartalmazó készítmények és elõállításuk |
| PL3542790T3 (pl) | 2012-03-22 | 2024-02-26 | Novo Nordisk A/S | Kompozycje zawierające substancję dostarczającą i ich przygotowanie |
| EP4324475A1 (en) | 2012-03-22 | 2024-02-21 | Novo Nordisk A/S | Compositions of glp-1 peptides and preparation thereof |
| JP6517690B2 (ja) | 2012-06-20 | 2019-05-22 | ノヴォ ノルディスク アー／エス | ペプチド及び送達剤を含む錠剤製剤 |
| US9340600B2 (en) | 2012-06-21 | 2016-05-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| RS67258B1 (sr) | 2012-07-01 | 2025-10-31 | Novo Nordisk As | Upotreba dugodelujućih glp-1 peptida |
| CN104717972A (zh) | 2012-10-17 | 2015-06-17 | 诺和诺德A/S（股份有限公司） | 用于口服肽递送的脂肪酸酰化氨基酸 |
| WO2014064215A1 (en) | 2012-10-24 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL |
| KR20210086717A (ko) | 2013-05-02 | 2021-07-08 | 노보 노르디스크 에이/에스 | Glp-1 화합물의 경구 투여 |
| ES2630106T3 (es) | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
| WO2016151018A1 (en) | 2015-03-24 | 2016-09-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| JP2018529749A (ja) | 2015-10-07 | 2018-10-11 | シプルメット・ゲーエムベーハー | ペプチド薬物を経口送達するための医薬製剤 |
| WO2018065634A1 (en) | 2016-10-07 | 2018-04-12 | Cyprumed Gmbh | Pharmaceutical compositions for the nasal delivery of peptide or protein drugs |
| IL322969A (en) | 2017-10-12 | 2025-10-01 | Novo Nordisk As | Semaglutide in medical therapy |
| WO2019149880A1 (en) | 2018-02-02 | 2019-08-08 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant |
| WO2019193204A1 (en) | 2018-04-06 | 2019-10-10 | Cyprumed Gmbh | Pharmaceutical compositions for the transmucosal delivery of therapeutic peptides and proteins |
| WO2019200594A1 (zh) | 2018-04-19 | 2019-10-24 | 杭州先为达生物科技有限公司 | 酰化的glp-1衍生物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN112898406B (zh) * | 2019-10-12 | 2023-11-10 | 深圳纳福生物医药有限公司 | 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用 |
| CN118420744A (zh) | 2019-12-30 | 2024-08-02 | 甘李药业股份有限公司 | 胰岛素衍生物 |
| AU2020418207A1 (en) * | 2019-12-30 | 2022-08-25 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting GLP-1 compound |
| CN111333714A (zh) * | 2020-03-05 | 2020-06-26 | 成都奥达生物科技有限公司 | 一种长效glp-1化合物 |
| US20230165939A1 (en) | 2020-04-29 | 2023-06-01 | Novo Nordisk A/S | Solid compositions comprising a glp-1 agonist and histidine |
| WO2022049310A1 (en) | 2020-09-07 | 2022-03-10 | Cyprumed Gmbh | Improved pharmaceutical formulations of glp-1 receptor agonists |
| EP4222176A4 (en) | 2020-09-30 | 2024-02-28 | Beijing QL Biopharmaceutical Co., Ltd. | POLYPEPTIDE CONJUGATES AND METHODS OF USE |
| WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
| CN115960202B (zh) * | 2021-10-09 | 2023-07-14 | 合肥天汇生物科技有限公司 | 一种glp-1类似物及其制备方法和应用 |
| CN115850438B (zh) * | 2021-12-28 | 2023-05-12 | 北京惠之衡生物科技有限公司 | 一种长效glp-1衍生物 |
| KR20240163717A (ko) | 2022-03-30 | 2024-11-19 | 베이징 큐엘 바이오파마슈티컬 컴퍼니 리미티드 | 폴리펩티드 접합체의 액체 약학 조성물 및 그의 사용 방법 |
| AU2023385357A1 (en) * | 2022-11-21 | 2025-06-05 | Eli Lilly And Company | Process for preparing a gip/glp1 dual agonist |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
| CN119569847A (zh) * | 2024-12-03 | 2025-03-07 | 中国科学院上海有机化学研究所 | Glp-1变体及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE164852T1 (de) * | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5968899A (en) * | 1994-06-03 | 1999-10-19 | Tsumura & Co. | Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| JP3149958B2 (ja) * | 1996-08-30 | 2001-03-26 | ノボ ノルディスク アクティーゼルスカブ | Ｇｌｐ―１誘導体 |
| US6268343B1 (en) * | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6458924B2 (en) * | 1996-08-30 | 2002-10-01 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US7235627B2 (en) * | 1996-08-30 | 2007-06-26 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| ES2237790T3 (es) * | 1996-11-12 | 2005-08-01 | Novo Nordisk A/S | Uso de peptidos glp-1. |
| WO1999043708A1 (en) | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| WO2000034331A2 (en) | 1998-12-07 | 2000-06-15 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Analogues of glp-1 |
| SI1180121T1 (en) | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
| ES2311560T3 (es) | 2000-12-07 | 2009-02-16 | Eli Lilly And Company | Proteinas de fusion glp-1. |
| JP2005501058A (ja) * | 2001-07-31 | 2005-01-13 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用 |
| AU2004231461B2 (en) | 2003-03-19 | 2009-11-12 | Eli Lilly And Company | Polyethelene glycol linked GLP-1 compounds |
| KR101241862B1 (ko) * | 2003-09-19 | 2013-03-13 | 노보 노르디스크 에이/에스 | 신규 ｇｌｐ-1 유도체 |
| JP2007537141A (ja) | 2003-12-18 | 2007-12-20 | ノボ ノルディスク アクティーゼルスカブ | 新規なｇｌｐ−１化合物 |
| ES2564167T3 (es) * | 2004-07-08 | 2016-03-18 | Novo Nordisk A/S | Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol |
| JP2008515856A (ja) * | 2004-10-07 | 2008-05-15 | ノボ ノルディスク アクティーゼルスカブ | 遅延性ｇｌｐ−１化合物 |
| EP1863537A2 (en) * | 2005-03-18 | 2007-12-12 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| JP5755398B2 (ja) * | 2005-03-18 | 2015-07-29 | ノヴォ ノルディスク アー／エス | 伸長されたｇｌｐ−１化合物 |
| WO2006097535A2 (en) * | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Peptide agonists of the glucagon family with secretin like activity |
| TWI372629B (en) * | 2005-03-18 | 2012-09-21 | Novo Nordisk As | Acylated glp-1 compounds |
| ES2672770T3 (es) * | 2007-09-05 | 2018-06-18 | Novo Nordisk A/S | Derivados del péptido-1 similar al glucagón y su uso farmacéutico |
-
2008
- 2008-09-05 WO PCT/EP2008/061833 patent/WO2009030774A1/en not_active Ceased
- 2008-09-05 JP JP2010523523A patent/JP2010538049A/ja not_active Withdrawn
- 2008-09-05 EP EP08803802.1A patent/EP2190873B1/en not_active Not-in-force
- 2008-09-05 ES ES08803802.1T patent/ES2550363T3/es active Active
- 2008-09-05 US US12/676,453 patent/US20100292133A1/en not_active Abandoned
- 2008-09-05 CN CN200880114458A patent/CN101842386A/zh active Pending
-
2014
- 2014-06-09 US US14/299,638 patent/US9657079B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008533105A5 (enExample) | ||
| RU2007134156A (ru) | Ацилированные glp-1 соединения | |
| RU2007134155A (ru) | Glp-1 соединения с увеличенным временем полужизни | |
| JP2013543853A5 (enExample) | ||
| JP2014529629A5 (enExample) | ||
| JP2014501712A5 (enExample) | ||
| WO2013148966A1 (en) | Transmucosal delivery of engineered polypeptides | |
| EP2729481B1 (en) | Engineered polypeptides having enhanced duration of action with reduced immunogenicity | |
| JP2012529463A5 (enExample) | ||
| CN103370083B (zh) | 具有增强的作用持续时间的工程化多肽 | |
| JP5476304B2 (ja) | グルカゴン様ペプチド−１誘導体及びそれらの医薬用途 | |
| JP2005528337A5 (enExample) | ||
| JP2023510218A (ja) | 長時間作用型ｇｌｐ－１化合物 | |
| JP2011520847A5 (enExample) | ||
| RU2006120079A (ru) | Производные глюкагоноподобного пептида-1 (glp-1) | |
| JP2022509568A5 (enExample) | ||
| US20090062192A1 (en) | Dimeric Peptide Agonists of the Glp-1 Receptor | |
| US20070093417A1 (en) | Novel GLP-1 analogues linked to albumin-like agents | |
| JP2012506402A5 (enExample) | ||
| JP2011520847A (ja) | 遅効型ｙ２及び／又はｙ４レセプターアゴニスト | |
| TW201010729A (en) | GIP-based mixed agonists for treatment of metabolic disorders and obesity | |
| JP2015517477A5 (enExample) | ||
| JP2017536343A5 (enExample) | ||
| CN107206044A (zh) | 用于受控且持续释放的elp融合蛋白 | |
| WO2016120380A1 (en) | Pharmaceutical composition for oral glp-1 administration comprising a tablet core and immediate release coating |